EGFR and breast cancer: In early-stage breast cancer, DDX5 expression along with overexpression of EGFR and Ki67, a nuclear marker for cell proliferation, positively correlates with a poor prognosis and invasiveness of tumors, a high risk of recurrence and worse survival in patients [68].